Kunlatida Maneenil

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 415 citations · Full text

Surgical Oncology, Hepatology, Medicine +8

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

B. Sangro, Stephen L. Chan, Robin Kate Kelley et al. · Annals of Oncology · 2024 · 254 citations · Full text

Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study

Bruno Sangro, Masatoshi Kudo, Joseph P. Erinjeri et al. · The Lancet · 2025 · 151 citations · Full text

Hepatology, Transarterial Chemoembolisation, Medicine +8

Sarcomatoid Carcinoma of the Lung: The Mayo Clinic Experience in 127 Patients

Kunlatida Maneenil, Zhiqiang Xue, Ming Liu et al. · Clinical Lung Cancer · 2017 · 97 citations

Mayo Clinic Experience, Medicine, Surgical Pathology +8

A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide

Piyawan Tienchaiananda, Wipada Nipondhkit, Kunlatida Maneenil et al. · Annals of Palliative Medicine · 2019 · 39 citations · Full text